05/02/2025
7:05 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/08/2025
3:45 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/07/2025
1:26 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/24/2025
6:57 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Flynn James E (Filed by)
| Form SCHEDULE 13D/A | |
03/21/2025
5:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/20/2025
3:03 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/20/2025
3:05 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/20/2025
6:02 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/20/2025
6:04 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/07/2025
4:12 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/05/2025
4:18 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for SPRY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. |
03/05/2025
4:19 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/04/2025
3:35 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/03/2025
11:06 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/31/2025
4:21 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form S-3ASR | |
01/13/2025
7:08 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/07/2025
5:24 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shawver Laura (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/06/2025
3:36 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/19/2024
3:20 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/19/2024
3:20 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
6:52 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
6:53 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
4:24 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/12/2024
4:41 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/12/2024
4:02 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/11/2024
5:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
5:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
4:31 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Dorsey Brian (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
3:48 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
10:15 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/09/2024
4:43 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/09/2024
4:25 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/09/2024
11:38 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
| Form 144/A | |
12/06/2024
6:15 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2024
4:30 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/05/2024
4:06 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/03/2024
4:25 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
6:01 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
5:22 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
3:42 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/27/2024
3:11 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Think NVDA’s run was epic? You ain’t seen nothin’ yet (Ad) Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade.
In 2023, it surged 239%. And in 2024, it soared another 171% on the year…
But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less? Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. |
11/21/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/21/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/15/2024
2:21 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/13/2024
7:16 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
DEERFIELD MANAGEMENT COMPANY, L.P. (0001009258) (Reporting)
Deerfield Mgmt III, L.P. (Reporting)
Deerfield Mgmt IV, L.P. (Reporting)
Deerfield Private Design Fund III, L.P. (Reporting)
Deerfield Private Design Fund IV, L.P. (Reporting)
Flynn James E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/13/2024
6:02 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/13/2024
6:00 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/17/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Scott Kathleen D. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/16/2024
3:01 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Scott Kathleen D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024
10:28 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Tanimoto Sarina (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024
6:02 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/10/2024
3:27 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/10/2024
3:28 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/23/2024
3:15 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/19/2024
3:26 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/19/2024
3:29 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/19/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
3:06 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
3:24 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
3:25 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/10/2024
9:31 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/28/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Thompson Peter A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/23/2024
5:41 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Thompson Peter A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/23/2024
5:38 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
ORBIMED ADVISORS LLC (Reporting)
OrbiMed Capital GP VI LLC (Reporting)
ORBIMED CAPITAL LLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:43 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
ORBIMED CAPITAL LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/21/2024
5:47 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:48 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:49 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Scott Kathleen D. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:51 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:51 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/20/2024
3:18 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Scott Kathleen D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/15/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/12/2024
6:59 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/18/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/18/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
11:07 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Tanimoto Sarina (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/11/2024
4:03 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/11/2024
4:04 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/28/2024
2:15 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/28/2024
5:46 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/24/2024
4:06 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Dadoo Rajeev (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/24/2024
4:13 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/21/2024
4:00 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
7:47 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Pratik Shah Living Trust dated June 15, 2011 (Filed by)
| Form SC 13D/A | |
06/17/2024
5:39 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shah Pratik (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/13/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/11/2024
6:18 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Pratik Shah Living Trust dated June 15, 2011 (Filed by)
| Form SC 13D/A | |
U.S. Stock Market Now on Verge of Collapse (Ad) The last time the U.S. economy looked like this, stocks didn't move for 16 years...
And many investors lost 80% of their wealth in real terms.
But before you touch any of your holdings – or buy anything – please review my latest warning about the U.S. stock market. It's free to watch. Click here to view my new presentation now. |
06/11/2024
10:36 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/07/2024
8:09 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Pratik Shah Living Trust dated June 15, 2011 (Reporting)
Shah Pratik (Reporting)
| Form 4/A | |
06/07/2024
8:11 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shah Pratik (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/06/2024
3:32 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Pratik Shah Living Trust dated June 15, 2011 (Reporting)
Shah Pratik (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
6:51 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
6:52 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/10/2024
6:01 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/09/2024
5:57 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2024
5:59 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Buy SPRY Stock Free SPRY Stock Alerts